Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03384875 · ClinicalTrials.gov registry record · NA
CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery
A NA study, sponsored by CytoSorbents.
- Terminated
- Registry status
- NA
- Development phase
- 186
- Enrollment target
NCT03384875 is a NA study that was terminated before completion, run by CytoSorbents. The registered enrollment target is 186 participants.
The verdict
NCT03384875, a NA study, was terminated before completion, sponsored by CytoSorbents.
- TERMINATED
- Registry status
- NA
- Development phase
- 186 participants
- Enrollment target
Study Summary
Prospective, multi-center, randomized, blinded, pivotal clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care plus treatment with the CytoSorb® device.
Interventions
- DEVICE CytoSorb
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2018-04-19 |
| Est. Completion | 2022-01-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03384875
The ClinicalTrials.gov registry entry for NCT03384875 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytoSorbents, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CytoSorb is the first listed.
NCT03384875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03384875 about?
NCT03384875 is a clinical study titled "CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery". Prospective, multi-center, randomized, blinded, pivotal clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care plus treatment with the CytoSorb® device.
What is the current status of trial NCT03384875?
This trial is currently terminated. It is a NA study. The enrollment target is 186 participants. The study started on 2018-04-19. Estimated completion is 2022-01-18.
What interventions are being tested in trial NCT03384875?
The interventions under investigation include: CytoSorb (DEVICE).
Who is sponsoring clinical trial NCT03384875?
This trial is sponsored by CytoSorbents, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.